Cresanto Global Limited
Cresanto Global Limited Live Price Chart
Cresanto Global Limited Technicals
| 20 Day | ₹ 3.433 |
| 50 Day | ₹ 2.917 |
| 100 Day | ₹ 2.510 |
| 200 Day | ₹ 2.572 |
| 20 Day | ₹ 3.378 |
| 50 Day | ₹ 2.783 |
| 100 Day | ₹ 2.278 |
| 200 Day | ₹ 2.039 |
Cresanto Global Limited Performance
| Previous Close | ₹ |
| High | ₹ |
| Volume | |
| 52W Range | ₹ - ₹ |
| Open | ₹ |
| Low | ₹ |
| Market Cap | ₹ 2 Cr |
Cresanto Global Limited Fundamentals
| ROCE | 76.509 |
| P/E Ratio | -14.070 |
| P/B Ratio | 0.000 |
| Industry P/E | 0.000 |
| Debt to Equity | 23.078 |
| ROE | 10.456 |
| EPS | -0.300 |
| Dividend Yield | 0.000 |
| Book Value | -6.304 |
| Face Value | 10.000 |
Cresanto Global Limited Financials
| Particulars | Y202503 | Y202403 | Y202303 | Y202203 | Y202103 |
|---|---|---|---|---|---|
| Total Revenue | 0.5259 | 0 | 0.020632 | 0 | 0.0066 |
| Total Expenses | 0.7064 | 0.1016 | 0.191575 | 0.082056 | 0.075431 |
| Profit After Tax | -0.1805 | -0.1016 | -0.170943 | -0.082056 | -0.068831 |
Cresanto Global Limited Shareholding Pattern
| Promoter Holdings | 32.274 % |
| FIIs | 0.000 % |
| DIIs | 0.959 % |
| MutualFund | 0.000 % |
| Retail | 44.145 % |
| Others - | 22.622 % |
About Cresanto Global Limited
History of Cresanto Global Limited
Cresanto Global Limited was initially incorporated as a private limited company on March 30, 1992, in the name of 'Raymed Labs Private Limited.' Pursuant to a special resolution passed by the members on September 27, 1993, the Company was converted into a public limited Company and renamed as Raymed Labs Limited. Further, on April 21, 2025, the members approved the change of name of the Company from Raymed Labs Limited to Cresanto Global Limited. The Company was earlier engaged in the business of pharmaceuticals. With the induction of the new management following the takeover of the Company, a strategic review of the existing business activities was undertaken. Considering the emerging opportunities, long-term growth prospects, and alignment with the vision of the new Promoters, the Board of Directors, at its meeting held on 27%' January, 2025, approved a proposal for alteration of the main objects of the Company. Pursuant to the said decision, the Company has shifted its focus from the pharmaceutical sector to the flexible packaging and trading business. The alteration of the main objects was subsequently placed before the shareholders for their approval and was duly approved at the Extra-Ordinary General Meeting of the Company held on 215 April, 2025. ...
